Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, announced today that
its President and CEO, Dr. Wayne Danter, will be a featured presenter at the
16th International p53 Workshop at the Stockholm Waterfront Congress Centre in
Sweden, which runs from June 15-19, 2014. This annual conference brings together
world-renowned scientists to discuss novel, basic, transitional, and clinical
research in the area of cancer biology with a focus on the p53 tumor suppressor
gene. 


Dr. Danter's presentation is scheduled for Monday, June 16 at 3:15 p.m. CEST,
and will highlight the Company's lead cancer drug candidate, COTI-2, as a novel
small molecule activator of mutant p53 protein for the treatment of susceptible
cancers. While at the conference, Dr. Danter will also be meeting with Professor
Sir David Lane, known for his joint discovery of the p53 tumor suppressor
protein in 1979. 


"I look forward to discussing our extensive preclinical findings regarding
COTI-2 with Professor Lane and several other p53 thought leaders and interested
parties," said Dr. Danter. "COTI-2 has a major mechanism of action that is
dependent on p53 gene mutation status in human cancer cells. We are convinced
that it is only a matter of time before the world recognizes the potentially
transformational impact of COTI-2 in the treatment of many cancers where there
is a p53 gene mutation present in afflicted patients."


Following Dr. Danter's scheduled presentation, the Company will upload his
slides to SlideShare at www.slideshare.net/CriticalOutcome. 


About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Notice to Readers

Information contained in this press release may contain certain statements,
which constitute "forward-looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement "... it is only a matter of time before the world recognizes the
potentially transformational impact of COTI-2 in the treatment of many cancers
where there is a p53 gene mutation present in afflicted patients." is a
forward-looking statement. Forward-looking statements by their nature are not
guarantees of future performance and are based upon management's current
expectations, estimates, projections and assumptions. COTI operates in a highly
competitive environment that involves significant risks and uncertainties, which
could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on
which these forward-looking statements are based to be reasonable, but as a
result of the many risk factors, cautions the reader that actual results could
differ materially from those expressed or implied in these forward-looking
statements. Information in this press release should be considered accurate only
as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory
authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com
Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Cotinga Pharmaceuticals Charts.
Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Cotinga Pharmaceuticals Charts.